eRF3b-37 inhibits the TGF-β1-induced activation of hepatic stellate cells by regulating cell proliferation, G0/G1 arrest, apoptosis and migration

  • Authors:
    • Zhengrong Xu
    • Tao Li
    • Man Li
    • Lei Yang
    • Rudan Xiao
    • Li Liu
    • Xin Chi
    • Dianwu Liu
  • View Affiliations

  • Published online on: September 26, 2018     https://doi.org/10.3892/ijmm.2018.3900
  • Pages: 3602-3612
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The therapeutic management of liver fibrosis remains an unresolved clinical problem. The activation of hepatic stellate cells (HSCs) serves a pivotal role in the formation of liver fibrosis. In our previous study, matrix‑assisted laser desorption/ionization time‑of‑flight mass spectrometry (MALDI‑TOF MS) was employed to identify potential serum markers for liver cirrhosis, such as eukaryotic peptide chain releasing factor 3b polypeptide (eRF3b‑37), which was initially confirmed by our group to serve a protective role in liver tissues in a C‑C motif chemokine ligand 4‑induced liver cirrhosis mouse model. Therefore, eRF3b‑37 was hypothesized to affect the activation state of HSCs, which was determined by the expression of pro‑fibrogenic associated factors in HSCs. In the present study, peptide synthesis technology was employed to elucidate the role of eRF3b‑37 in the expression of pro‑fibrogenic factors induced by transforming growth factor‑β1 (TGF‑β1) in LX‑2 cells that were treated with either control, TGF‑β1 and TGF‑β1+eRF3b‑37. 3‑(4,5‑Dimethyl‑2‑thiazolyl)‑2,5‑diphenyltetrazolium bromide and flow cytometric assays, and fluorescent microscope examinations were performed to evaluate the effects of eRF3b‑37 on proliferation viability, G0/G1 arrest, apoptosis and cell migration. The results of the present study indicated that eRF3b‑37 inhibited the activation of HSCs. The increased mRNA and protein expression of the pro‑fibrogenic factors collagen I, connective tissue growth factor and α‑smooth muscle actin (SMA) stimulated by TGF‑β1 were reduced by eRF3b‑37 via the following mechanisms: i) Inhibiting LX‑2 cell proliferation, leading to G0/G1 cell cycle arrest and inhibition of DNA synthesis by downregulating the mRNA expressions of Cyclin D1 and cyclin dependent kinase‑4, and upregulating the levels of P21; ii) increasing cell apoptosis by upregulating the mRNA level of B‑cell lymphoma-2 (Bcl‑2)‑associated X protein (Bax) and Fas, and downregulating the expression of Bcl‑2; and iii) reducing cell migration by downregulating the mRNA and protein expression of α‑SMA. In addition, eRF3b‑37 is thought to serve a role in HSCs by inhibiting TGF‑β signaling. Therefore, eRF3b‑37 may be a novel therapeutic agent for targeting HSCs for hepatic fibrosis.

References

1 

Tang LX, He RH, Yang G, Tan JJ, Zhou L, Meng XM, Huang XR and Lan HY: Asiatic acid inhibits liver fibrosis by blocking TGF-beta/Smad signaling in vivo and in vitro. PLoS One. 7:e313502012. View Article : Google Scholar : PubMed/NCBI

2 

Gressner AM, Yagmur E, Lahme B, Gressner O and Stanzel S: Connective tissue growth factor in serum as a new candidate test for assessment of hepatic fibrosis. Clin Chem. 52:1815–1817. 2006. View Article : Google Scholar : PubMed/NCBI

3 

Tsukada S, Parsons CJ and Rippe RA: Mechanisms of liver fibrosis. Clin Chim Acta. 364:33–60. 2006. View Article : Google Scholar

4 

Zhang CY, Yuan WG, He P, Lei JH and Wang CX: Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets. World J Gastroenterol. 22:10512–10522. 2016. View Article : Google Scholar

5 

Peelman F, Waelput W, Iaerentant H, Lavens D, Eyckerman S, Zabeau L and Tavenier J: Leptin: Linking adipocyte metabolism with cardiovascular and autoimmune diseases. Prog Lipid Res. 43:283–301. 2004. View Article : Google Scholar : PubMed/NCBI

6 

Li L, Wang JY, Yang CQ and Jiang W: Effect of RhoA on transforming growth factor β1-induced rat hepatic stellate cell migration. Liver Int. 32:1093–1102. 2012. View Article : Google Scholar : PubMed/NCBI

7 

Bataller R and Brenner DA: Hepatic satellite cells as a target for the treatment of liver fibrosis. Semin Liver Dis. 21:437–451. 2001. View Article : Google Scholar : PubMed/NCBI

8 

Chung YJ, Lee JI, Chong S, Seok JW, Park SJ, Jang HW, Kim SW and Chung JH: Anti-proliferative effect and action mechanism of dexamethasone in human medullary thyroid cancer cell line. Endocr Res. 36:149–157. 2011. View Article : Google Scholar : PubMed/NCBI

9 

Qi W, Chen X, Poronnik P and Pollock CA: Transforming growth factor- beta/connective tissue growth factor axis in the kidney. Int J Biochem Cell Biol. 40:9–13. 2008. View Article : Google Scholar

10 

Marquez-Aguirre A, Sandoval-Rodriguez A, Gonzalez-Cuevas J, Bueno-Topete M, Navarro-Partida J, Arellano-Olivera I, Lucano-Landeros S and Armendariz-Borunda J: Adenoviral delivery of dominant-negative transforming growth factor beta type II receptor upregulates transcriptional repressor SKI-like oncogene, decreases matrix metalloproteinase 2 in hepatic stellate cell and prevents liver fibrosis in rats. J Gene Med. 11:207–219. 2009. View Article : Google Scholar : PubMed/NCBI

11 

George J, Roulot D, Koteliansky VE and Bissell DM: In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: A potential new therapy for hepatic fibrosis. Proc Natl Acad Sci USA. 96:12719–12724. 1999. View Article : Google Scholar : PubMed/NCBI

12 

Li M, Wang J, Dai E and Liu D: Identification and investigation of disease-related peptides in sera from patients with chronic hepatitis B. Wei Sheng Yan Jiu. 40:315–319. 2011.In Chinese. PubMed/NCBI

13 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar

14 

Swanton C: Cell-cycle targeted therapies. Lancet Oncol. 5:27–36. 2004. View Article : Google Scholar : PubMed/NCBI

15 

Saile B, Matthes N, Knittel T and Ramadori G: Transforming growth factor beta and tumor necrosis factor alpha inhibit both apoptosis and proliferation of activated rat hepatic stellate cells. Hepatology. 30:196–202. 1999. View Article : Google Scholar : PubMed/NCBI

16 

Saile B, Matthes N, EI Armouche H, Neubauer K and Ramadori G: The bcl, NFkappaB and p53/p21WAF1 systems are involved in spontaneous apoptosis and in the anti-apoptotic effect of TGF-beta or TNF-alpha on activated hepatic stellate cells. Eur J Cell Biol. 80:554–561. 2001. View Article : Google Scholar : PubMed/NCBI

17 

Breitkopf K, Godoy P, Ciuclan L, Singer MV and Dooley S: TGF-beta/Smad signaling in the injured liver. Z Gastroenterol. 44:57–66. 2006. View Article : Google Scholar : PubMed/NCBI

18 

Gao R, Ball DK, Perbal B and Brigstock DR: Connective tissue growth factor (CCN2) induces c-fos gene activation and cell proliferation through p42/44 MAP kinase (ERK1/2) in primary rat hepatic stellate cells. J Hepatol. 40:431–438. 2004. View Article : Google Scholar : PubMed/NCBI

19 

Deng ZY, Li J, Jin Y, Chen XL and Lü XW: Effect of oxymatrine on the p38 mitogen-activated protein kinases signalling pathway in rats with CCl4 induced hepatic fibrosis. Chinese Med J (Engl). 122:1449–1454. 2009.

20 

Kocabayoglu P and Friedman SL: Cellular basis of hepatic fibrosis and its role in inflammation and cancer. Front Biosci (Schol Ed). 5:217–230. 2013. View Article : Google Scholar

21 

Shimada H, Staten NR and Rajagopalan LE: TGF-β1 mediated activation of Rho kinase induces TGF-β2 and endothelin-1 expression in human hepatic stellate cells. J Hepatol. 54:521–528. 2011. View Article : Google Scholar

22 

Higashi T, Friedman SL and Hoshida Y: Hepatic stellate cells as key target in liver fibrosis. Adv Drug Deliv Rev. 121:27–42. 2017. View Article : Google Scholar : PubMed/NCBI

23 

Qi W, Twigg S, Chen X, Polhill TS, Poronnik P, Gilbert RE and Pollock CA: Integrated actions of transforming growth factor-beta1 and connective tissue growth factor in renal fibrosis. Am J Physiol Renal Physiol. 288:F800–F809. 2005. View Article : Google Scholar

24 

Yokoi H, Sugawara A, Mukoyama M, Mori K, Makino H, Suganami T, Nagae T, Yahata K, Fujinaga Y, Tanaka I and Nakao K: Role of connective tissue growth factor in profibrotic action of transforming growth factor-beta: A potential target for preventing renal fibrosis. Am J Kidney Dis. 38(4 Suppl 1): S134–S138. 2001. View Article : Google Scholar : PubMed/NCBI

25 

Cao YL, Duan Y, Zhu LX, Zhan YN, Min SX and Jin AM: TGF-β1, in association with the increased expression of connective tissue growth factor, induce the hypertrophy of the ligamentum flavum through the p38 MAPK pathway. Int J Mol Med. 38:391–398. 2016. View Article : Google Scholar : PubMed/NCBI

26 

Williams EJ, Gaça MD, Brigstock DR, Arthur MJ and Benyon RC: Increased expression of connective tissue growth factor in fibrotic human liver and in activated hepatic stellate cells. J Hepatol. 32:754–761. 2000. View Article : Google Scholar : PubMed/NCBI

27 

Hopkins M, Tyson JJ and Novák B: Cell-cycle transitions: A common role for stoichiometric inhibitors. Mol Biol Cell. 28:3437–3446. 2017. View Article : Google Scholar : PubMed/NCBI

28 

Jung KH, Kim JK, Noh JH, Eun JW, Bae HJ, Xie HJ, Ahn YM, Park WS, Lee JY and Nam SW: Targeted disruption of Nemo-like kinase inhibits tumor cell growth by simultaneous suppression of cyclin D1 and CDK2 in human hepatocellular carcinoma. J Cell Biochem. 110:686–696. 2010. View Article : Google Scholar

29 

Meng L, Feng B, Tao H, Yang T, Meng Y, Zhu W and Huang C: A novel antiestrogen agent (3R,6R)-bassiatin inhibits cell proliferation and cell cycle progression by repressing Cyclin D1 expression in 17β-estradiol-treated MCF-7 cells. Cell Biol Int. 35:599–605. 2011. View Article : Google Scholar : PubMed/NCBI

30 

Lange C, Huttner WB and Calegari F: Cdk4/CyclinD1 overex-pression in neural stem cells shortens G1, delays neurogenesis, and promotes the generation and expansion of basal progenitors. Cell Stem Cell. 5:320–331. 2009. View Article : Google Scholar : PubMed/NCBI

31 

Qin LF and Ng IO: Exogenous expression of p21 (WAF1/CIP1) exerts cell growth inhibition and enhances sensitivity to cisplatin in hepatoma cells. Cancer Lett. 172:7–15. 2001. View Article : Google Scholar : PubMed/NCBI

32 

Cazzalini O, Perucca P, Riva F, Stivala LA, Bianchi L, Vannini V, Ducommun B and Prosperi E: p21CDKN1A does not interfere with loading of PCNA at DNA replication sites, but inhibits subsequent binding of DNA polymerase delta at the G1/S phase transition. Cell Cycle. 2:596–603. 2003. View Article : Google Scholar : PubMed/NCBI

33 

Green DR: Apoptotic pathways: Paper wraps stone blunts scissors. Cell. 102:1–4. 2000. View Article : Google Scholar : PubMed/NCBI

34 

Peng X, Yu Z, Liang N, Chi X, Li X, Jiang M, Fang J, Cui H, Lai W, Zhou Y and Zhou S: The mitochondrial and death receptor pathways involved in the thymocytes apoptosis induced by aflatoxin B1. Oncotarget. 7:12222–12234. 2016.PubMed/NCBI

35 

Kawada N: Human hepatic stellate cells are resistant to apop-tosis: Implications for human fibrogenic liver disease. Gut. 55:1073–1074. 2006. View Article : Google Scholar : PubMed/NCBI

36 

Novo E, Marra F, Zamara E, Valfrè di Bonzo L, Monitillo L, Cannito S, Petrai I, Mazzocca A, Bonacchi A, De Franco RS, et al: Overexpression of Bcl-2 by activated human hepatic stellate cells: Resistance to apoptosis as a mechanism of progressive hepatic fibrogenesis in humans. Gut. 55:1174–1182. 2006. View Article : Google Scholar : PubMed/NCBI

37 

Saile B, Knittel T, Matthes N, Schott P and Ramadori G: CD95/CD95L-mediated apoptosis of the hepatic stellate cell. A mechanism terminating uncontrolled hepatic stellate cell proliferation during hepatic tissue repair. Am J Pathol. 151:1265–1272. 1997.PubMed/NCBI

38 

Tan C, Dlugosz PJ, Peng J, Zhang Z, Lapolla SM, Plafker SM, Andrews DW and Lin J: Auto-activation of the apoptosis protein Bax increases mitochondrial membrane permeability and is inhibited by Bcl-2. J Biol Chem. 281:14764–14775. 2006. View Article : Google Scholar : PubMed/NCBI

39 

Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, Arteaga CL and Moses HL: Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferen-tiation through a RhoA-dependent mechanism. Mol Biol Cell. 12:27–36. 2001. View Article : Google Scholar : PubMed/NCBI

40 

Wang Y, Ma J, Chen L, Xie XL and Jiang H: Inhibition of focal adhesion kinase on hepatic stellate-cell adhesion and migration. Am J Med Sci. 353:41–48. 2017. View Article : Google Scholar : PubMed/NCBI

41 

Hinz B, Celetta G, Tomasek JJ, Gabbiani G and Chaponnier C: Alpha-smooth muscle actin expression upregulates fibroblast contractile activity. Mol Biol Cell. 12:2730–2741. 2001. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

December 2018
Volume 42 Issue 6

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Xu, Z., Li, T., Li, M., Yang, L., Xiao, R., Liu, L. ... Liu, D. (2018). eRF3b-37 inhibits the TGF-β1-induced activation of hepatic stellate cells by regulating cell proliferation, G0/G1 arrest, apoptosis and migration. International Journal of Molecular Medicine, 42, 3602-3612. https://doi.org/10.3892/ijmm.2018.3900
MLA
Xu, Z., Li, T., Li, M., Yang, L., Xiao, R., Liu, L., Chi, X., Liu, D."eRF3b-37 inhibits the TGF-β1-induced activation of hepatic stellate cells by regulating cell proliferation, G0/G1 arrest, apoptosis and migration". International Journal of Molecular Medicine 42.6 (2018): 3602-3612.
Chicago
Xu, Z., Li, T., Li, M., Yang, L., Xiao, R., Liu, L., Chi, X., Liu, D."eRF3b-37 inhibits the TGF-β1-induced activation of hepatic stellate cells by regulating cell proliferation, G0/G1 arrest, apoptosis and migration". International Journal of Molecular Medicine 42, no. 6 (2018): 3602-3612. https://doi.org/10.3892/ijmm.2018.3900